Emerging trends in the treatment of advanced basal cell carcinoma.

[1]  E. Basch,et al.  The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events , 2018, Journal of Patient-Reported Outcomes.

[2]  Ahmed Kamel,et al.  Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  G. Daniels,et al.  Rescue therapy with anti‐programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases , 2016, The British journal of dermatology.

[4]  Philip R. Cohen,et al.  Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy , 2016, npj Genomic Medicine.

[5]  R. Dummer,et al.  The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. , 2016, Journal of the American Academy of Dermatology.

[6]  S. Antonarakis,et al.  Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma , 2016, Nature Genetics.

[7]  L. Fecher,et al.  Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors , 2015, Biologics : targets & therapy.

[8]  K. Sarin,et al.  An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib , 2015, Clinical Cancer Research.

[9]  A. Hauschild,et al.  Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. , 2015, Journal of the American Academy of Dermatology.

[10]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. , 2015, The Lancet. Oncology.

[11]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[12]  K. Haustermans,et al.  Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened , 2015, Oncotarget.

[13]  A. Kauvar,et al.  Consensus for Nonmelanoma Skin Cancer Treatment: Basal Cell Carcinoma, Including a Cost Analysis of Treatment Methods , 2015, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  C. Rudin,et al.  Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. , 2015, Cancer cell.

[15]  P. Ascierto,et al.  Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. , 2015, Future oncology.

[16]  S. Pilotti,et al.  Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma , 2015, Molecular oncology.

[17]  N. Basset-Seguin,et al.  Efficacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma , 2015, Molecular Cancer Therapeutics.

[18]  A. El-Khoueiry,et al.  A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[19]  A. Paulussen,et al.  Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[20]  A. Wysong,et al.  An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[21]  Jianming Xu,et al.  GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis , 2014, Oncotarget.

[22]  P. Dziewulski,et al.  Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective , 2014, British Journal of Cancer.

[23]  D. Schadendorf,et al.  Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. , 2014, The oncologist.

[24]  A. Adjei,et al.  Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. , 2014, Cancer treatment reviews.

[25]  A. Hauschild,et al.  Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. , 2014 .

[26]  J. Sligh,et al.  Defining locally advanced Basal cell carcinoma. , 2014, Journal of drugs in dermatology : JDD.

[27]  K. Peris,et al.  Update of the European guidelines for basal cell carcinoma management , 2014, European Journal of Dermatology.

[28]  P. Beachy,et al.  Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Dummer,et al.  A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[30]  D. Hayes,et al.  Hedgehog–GLI Signaling Inhibition Suppresses Tumor Growth in Squamous Lung Cancer , 2014, Clinical Cancer Research.

[31]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[32]  J. Hainsworth,et al.  Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. , 2014, Journal of the American Academy of Dermatology.

[33]  A. Colevas,et al.  Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma , 2013, The British journal of dermatology.

[34]  A. Chang,et al.  Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. , 2012, Archives of dermatology.

[35]  A. Cognetta,et al.  Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[36]  B. Coldiron,et al.  AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. , 2012, Journal of the American Academy of Dermatology.

[37]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[38]  R. Gonzalez,et al.  Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors. , 2012, Seminars in oncology.

[39]  C. Compton,et al.  Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas , 2012 .

[40]  A. Kessinger,et al.  Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. , 2011, Cancer treatment reviews.

[41]  Jingwu Xie,et al.  Hedgehog signaling in skin cancers. , 2011, Cellular signalling.

[42]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[43]  V. Samarasinghe,et al.  Focus on Basal Cell Carcinoma , 2010, Journal of skin cancer.

[44]  Lixin Lang,et al.  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. , 2010 .

[45]  P. LoRusso,et al.  Review: Targeting the Hedgehog pathway in cancer , 2010, Therapeutic advances in medical oncology.

[46]  J. Low,et al.  The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment , 2010, Clinical Cancer Research.

[47]  R. Toftgård,et al.  Hedgehog beyond medulloblastoma and basal cell carcinoma. , 2010, Biochimica et biophysica acta.

[48]  F. D. de Sauvage,et al.  Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. , 2009, Trends in pharmacological sciences.

[49]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[50]  E. Epstein.  Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.

[51]  C. Morton,et al.  Guidelines for the management of basal cell carcinoma , 2008, The British journal of dermatology.

[52]  J. Reiter,et al.  The primary cilium at the crossroads of mammalian hedgehog signaling. , 2008, Current topics in developmental biology.

[53]  J. Reiter,et al.  The primary cilium at the crossroads of mammalian hedgehog signaling. , 2008, Current topics in developmental biology.

[54]  H. Kerl,et al.  Epidemiology and aetiology of basal cell carcinoma , 2007, The British journal of dermatology.

[55]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[56]  R. Klein,et al.  Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory , 2005, Genetics in Medicine.

[57]  B. Diffey,et al.  Skin cancer incidence and the ageing population , 2005, The British journal of dermatology.

[58]  Christopher J. Arpey,et al.  Aggressive basal cell carcinoma: Presentation, pathogenesis, and management , 2004, Cancer and Metastasis Reviews.

[59]  R. Dummer,et al.  Superficial radiotherapy for patients with basal cell carcinoma , 2003, Cancer.

[60]  Marina Pasca di Magliano,et al.  Hedgehog signalling in cancer formation and maintenance , 2003, Nature Reviews Cancer.

[61]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[62]  Andrew P McMahon,et al.  Developmental roles and clinical significance of hedgehog signaling. , 2003, Current topics in developmental biology.

[63]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[64]  Michael Dean,et al.  Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome , 1996, Cell.

[65]  R. Myers,et al.  Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.

[66]  O. Hansen,et al.  Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. , 1996, Acta oncologica.

[67]  M. Greene,et al.  Developmental defects in gorlin syndrome related to a putative tumor suppressor gene on chromosome 9 , 1992, Cell.

[68]  B. Guyuron,et al.  Long-term survival following nodal metastases from basal cell carcinoma. , 1990, Annals of plastic surgery.

[69]  R. Carroll,et al.  Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. , 1989, The Journal of dermatologic surgery and oncology.

[70]  R. Carroll,et al.  Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. , 1989, The Journal of dermatologic surgery and oncology.

[71]  H. von Domarus,et al.  Metastatic basal cell carcinoma , 1984 .